Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinicopathological characteristics of patients who underwent R0 resection and adjuvant therapy for pancreatic cancer

From: Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment

Variables N = 351
Age 63.3 ± 9.3
Sex
 - Female 148 (42.2%)
 - Male 203 (57.8%)
Body mass index, kg/m2 22.9 ± 2.7
ECOG
 - 0 289 (82.3%)
 - 1 62 (17.7%)
Charlson’s comorbidity index 4.6 ± 1.3
Tumor location
 - Head/uncinate 225 (64.1%)
 - Body 62 (17.7%)
 - Tail 52 (14.8%)
 - Overlapping 12 (3.4%)
Surgery type
 - Pancreaticoduodenectomy 232 (66.1%)
 - Distal pancreatectomy 107 (30.5%)
 - Total 7 (2.0%)
 - Subtotal 4 (1.1%)
 - Central pancreatectomy 1 (0.3%)
Histologic grade
 - Well differentiated 28 (8.0%)
 - Moderately differentiated 289 (82.3%)
 - Poorly differentiated 31 (8.8%)
 - Undifferentiated 3 (0.9%)
pT stage (AJCC 8th)
 - 1a / 1b / 1c 2 (0.6%) / 4 (1.1%) / 61 (17.4%)
 - 2 235 (67.0%)
 - 3 45 (12.8%)
 - 4 4 (1.1%)
Number of examined LNs 18.4 ± 11.7
Number of involved LNs 1.8 ± 2.6
pN stage (AJCC 8th)
 - 0 150 (42.7%)
 - 1 135 (38.5%)
 - 2 66 (18.8%)
LNR 0.1 ± 0.2
LODDS −1.0 ± 0.5
Lymphovascular invasion 158 (45.0%)
Perineural invasion 293 (83.5%)
Preoperative laboratory findings
 - WBC, 103/μL 6.2 ± 1.9
 - Hemoglobin, g/dL 12.9 ± 1.5
 - Platelet, 103/μL 248.0 ± 79.5
 - Albumin, g/dL 4.2 ± 3.4
 - Total bilirubin, mg/dL 2.2 ± 3.5
 - AST, IU/L 43.1 ± 49.0
 - ALT, IU/L 65.7 ± 92.6
 - ALP, IU/L 157.0 ± 162.7
 - CA 19-9, U/mL 642.3 ± 1563.6
 - CEA, ng/mL 21.5 ± 300.0
  1. ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, LNR lymph-node ratio, LODDS log odds of positive lymph nodes, WBC white blood cell, AST aspartate Aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen